

# CQLabs

REINVENTING PURPOSE™



CQLabs  
**MicroCBD™**  
*(cannabidiol xs) capsules*  
Patent Pending

Please See Important Safety Information On Back  
And Accompanying Full User Information.

# REINVENTING PURPOSE™

CQLabs  
**MicroCBD™**  
(cannabidiol xs) capsules  
Patent Pending

## The CQLabs CBDispersion System™

Oral administration of cannabidiol is already proven effective for many conditions. However bioavailability is a major concern. The CQLabs proprietary CBDispersion System™ has addressed this precise issue. The CQLabs CBDispersion System™ has increased the bioavailability by a factor of 3-4x. This enables users to administer and process less cannabidiol and at the same time obtain greater results.



### ALL CBD'S ARE NOT CREATED EQUAL

- ✓ Patent-Pending Compound.
- ✓ Data Backed by Science.
- ✓ Water Soluble.
- ✓ Consume Less Product. Obtain Superior Results.
- ✓ Rapid Absorption vs. Standard CBD's.
- ✓ Proprietary Delivery System.
- ✓ Laboratory Tested for Purity and Potency.
- ✓ Endless Applications.

[www.CQLabs.com](http://www.CQLabs.com)


CQLabs  
**MicroCBD™**  
*(cannabidiol xs) capsules*  
 Patent Pending

## DESCRIPTION

CQLabs MicroCBD™, for oral administration, contains a patent-pending form of water-soluble, nano-emulsified cannabidiol.


CQLabs MicroCBD™, is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is also soluble in water as well as oil.

The chemical name for cannabidiol is:  
 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol.  
 Its molecular formula is C<sub>21</sub>H<sub>30</sub>O<sub>2</sub>, and the molecular weight is 314.469 g/mol.



## Bioavailability of MicroCBD™ vs. Standard CBD's

*(cannabidiol xs) capsules*



### HOW SUPPLIED

CQLabs MicroCBD™ (cannabidiol xs) Capsules are available as follows:  
 8 mg Capsule 30 count bottle  
 8 mg Capsule 60 count bottle  
 16 mg Capsule 30 count bottle  
 16 mg Capsule 60 count bottle  
 62.5 mg Capsule count bottle

Bottles should be stored at controlled room temperature 15 to 30°C (59 - 86°F)  
 Protect from heat, light, and moisture.  
 This product's label may have been updated. For current information, please visit CQLabs.com.

### Information for users

Users should be instructed to report any of the following: nausea, vomiting, changes in skin color, swelling, and or any other abnormal conditions after starting treatment.

### Laboratory Test

Cannabidiol levels should be checked periodically in users receiving long-term cannabidiol administration.

### The CQLabs CBDispersion System™

Oral administration of cannabidiol is already proven effective for many conditions. However bioavailability is a major concern. The CQLabs proprietary CBDispersion System™ has addressed this precise issue. The CQLabs CBDispersion System™ has increased the bioavailability by a factor of 3-4x. This enables users to administer and process less cannabidiol and at the same time obtain greater results.

### DOSAGE AND ADMINISTRATION

Prior to initiating CQLabs MicroCBD™ (cannabidiol xs), consult your healthcare professional. CQLabs MicroCBD™ is for oral administration only. The suggested dosage for CQLabs MicroCBD™ Capsules varies depending on the age, sex, and condition of the individual user. Dosage is adjusted based on the users response and any appearance of adverse reactions.

### OVERDOSAGE

There have been no reports with cannabidiol.

### DEPENDENCE

Behaviors Associated with Addiction  
 Continued abuse of cannabidiol and other cannabidoids, leading to addiction is characterized by the following behaviors:

- Taking cannabidiol dosages greater than recommended
- Giving a higher priority to cannabidiol use than other obligations
- Continued cannabidiol use despite medical and social issues due to use
- Spending excessive amounts of time trying to obtain cannabidiol
- Inability to discontinue use despite multiple attempts

Individuals taking supertherapeutic doses of cannabidiol may experience withdrawal symptoms. These withdrawal may include but are not limited to craving, restlessness, irritability, insomnia and anxiety. Dependence in individuals using recommended doses of cannabidiol for recommended indications has not been documented.

\*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.